Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Oct 15, 2026; 18(10): 122796
Published online Oct 15, 2026. doi: 10.4251/wjgo.122796
Published online Oct 15, 2026. doi: 10.4251/wjgo.122796
Peripheral blood marker changes predict response and prognosis in locally advanced gastric cancer with neoadjuvant sintilimab plus XELOX
Yan Wu, Mi-Mi Xu, Guo-Lin Wang, Wen-Di Du, Xin-Hui Su, Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Author contributions: Wu Y formulated the conceptual framework and undertook the primary drafting of this paper; Xu MM developed the analytical methods and study design for this research; Wang GL performed the data collection and collation for this study; Du WD constructed the tables and figures for the article; Su XH was responsible for revising and editing the manuscript. All authors approved the final version to publish.
AI contribution statement: AI tools only serve to correct grammar.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine, No. 20230569.
Informed consent statement: Individual informed consent was waived for this retrospective analysis.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The dataset is available upon request from the corresponding author.
Corresponding author: Xin-Hui Su, MD, PhD, Academic Fellow, Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. suxinhui@zju.edu.cn
Received: April 29, 2026
Revised: June 11, 2026
Accepted: June 30, 2026
Published online: October 15, 2026
Processing time: 141 Days and 23.2 Hours
Revised: June 11, 2026
Accepted: June 30, 2026
Published online: October 15, 2026
Processing time: 141 Days and 23.2 Hours
Core Tip
Core Tip: This study investigated the changes in peripheral blood inflammatory markers and T-cell subsets in patients with gastric cancer at baseline and after neoadjuvant chemotherapy with sintilimab combined with XELOX. Results indicate that high post-treatment monocyte-to-lymphocyte ratio levels are associated with a favorable treatment response, a greater relative change in the proportion of CD8+ T cells may be associated with better prognosis, and diffuse-type gastric cancer may be associated with poorer clinical outcomes. These easily detectable biomarkers offer a new perspective for predicting treatment response and assessing prognosis; however, further validation is required.